

10/544093

**RAW SEQUENCE LISTING**

**The Biotechnology Systems Branch of the Scientific and Technical  
Information Center (STIC) no errors detected.**

Application Serial Number: 10/544,093  
Source: PUT  
Date Processed by STIC: 4/28/06

***ENTERED***



PCT

## RAW SEQUENCE LISTING

DATE: 04/28/2006

PATENT APPLICATION: US/10/544,093

TIME: 09:51:40

Input Set : A:\9820US.ST25.txt

Output Set: N:\CRF4\04282006\J544093.raw

3 <110> APPLICANT: Yednock, Ted  
 4 Vasquez, Nicki  
 5 Bard, Frederique  
 6 Seubert, Peter A.  
 8 <120> TITLE OF INVENTION: ACTIVE IMMUNIZATION TO GENERATE ANTIBODIES TO  
 SOLUBLE A-BETA FOR  
 9 PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE  
 11 <130> FILE REFERENCE: 15270J-009820US  
 13 <140> CURRENT APPLICATION NUMBER: US 10/544,093  
 C--> 14 <141> CURRENT FILING DATE: 2005-08-01  
 16 <150> PRIOR APPLICATION NUMBER: WO PCT/US2004/002856  
 17 <151> PRIOR FILING DATE: 2004-01-31  
 19 <150> PRIOR APPLICATION NUMBER: US 60/444,150  
 20 <151> PRIOR FILING DATE: 2003-02-01  
 22 <160> NUMBER OF SEQ ID NOS: 27  
 24 <170> SOFTWARE: PatentIn version 3.2  
 26 <210> SEQ ID NO: 1  
 27 <211> LENGTH: 42  
 28 <212> TYPE: PRT  
 29 <213> ORGANISM: Homo sapiens  
 31 <400> SEQUENCE: 1  
 33 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys  
 34 1 5 10 15  
 37 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile  
 38 20 25 30  
 41 Gly Leu Met Val Gly Gly Val Val Ile Ala  
 42 35 40  
 45 <210> SEQ ID NO: 2  
 46 <211> LENGTH: 5  
 47 <212> TYPE: PRT  
 48 <213> ORGANISM: Artificial  
 50 <220> FEATURE:  
 51 <223> OTHER INFORMATION: Reversomer of A-beta 1-5  
 53 <400> SEQUENCE: 2  
 55 Arg Phe Glu Ala Asp  
 56 1 5  
 59 <210> SEQ ID NO: 3  
 60 <211> LENGTH: 17  
 61 <212> TYPE: PRT  
 62 <213> ORGANISM: Artificial  
 64 <220> FEATURE:  
 65 <223> OTHER INFORMATION: Artificial peptide derived from residues 323-339  
 of ovalbumin.  
 67 <400> SEQUENCE: 3

P.7

69 Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn Glu Ala Gly

## RAW SEQUENCE LISTING

DATE: 04/28/2006

PATENT APPLICATION: US/10/544,093

TIME: 09:51:40

Input Set : A:\9820US.ST25.txt

Output Set: N:\CRF4\04282006\J544093.raw

```

70 1          5          10          15
73 Arg
77 <210> SEQ ID NO: 4
78 <211> LENGTH: 16
79 <212> TYPE: PRT
80 <213> ORGANISM: Plasmodium sp.
82 <400> SEQUENCE: 4
84 Glu Lys Lys Ile Ala Lys Met Glu Lys Ala Ser Ser Val Phe Asn Val
85 1          5          10          15
88 <210> SEQ ID NO: 5
89 <211> LENGTH: 10
90 <212> TYPE: PRT
91 <213> ORGANISM: Hepatitis B virus
93 <400> SEQUENCE: 5
95 Phe Phe Leu Leu Thr Arg Ile Leu Thr Ile
96 1          5          10
99 <210> SEQ ID NO: 6
100 <211> LENGTH: 19
101 <212> TYPE: PRT
102 <213> ORGANISM: Artificial
104 <220> FEATURE:
105 <223> OTHER INFORMATION: Heat Shock Protein 65 fragment
107 <400> SEQUENCE: 6
109 Asp Gln Ser Ile Gly Asp Leu Ile Ala Glu Ala Met Asp Lys Val Gly
110 1          5          10          15
113 Asn Glu Gly
117 <210> SEQ ID NO: 7
118 <211> LENGTH: 14
119 <212> TYPE: PRT
120 <213> ORGANISM: Artificial
122 <220> FEATURE:
123 <223> OTHER INFORMATION: Bacille Calmette-Guerin fragment
125 <400> SEQUENCE: 7
127 Gln Val His Phe Gln Pro Leu Pro Pro Ala Val Val Lys Leu
128 1          5          10
131 <210> SEQ ID NO: 8
132 <211> LENGTH: 15
133 <212> TYPE: PRT
134 <213> ORGANISM: Clostridium tetani
136 <400> SEQUENCE: 8
138 Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
139 1          5          10          15
142 <210> SEQ ID NO: 9
143 <211> LENGTH: 21
144 <212> TYPE: PRT
145 <213> ORGANISM: Clostridium tetani
147 <400> SEQUENCE: 9
149 Phe Asn Asn Phe Thr Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser
150 1          5          10          15

```

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/544,093

DATE: 04/28/2006

TIME: 09:51:41

Input Set : A:\9820US.ST25.txt

Output Set: N:\CRF4\04282006\J544093.raw

```

153 Ala Ser His Leu Glu
154                20
157 <210> SEQ ID NO: 10
158 <211> LENGTH: 16
159 <212> TYPE: PRT
160 <213> ORGANISM: Human immunodeficiency virus
162 <400> SEQUENCE: 10
164 Lys Gln Ile Ile Asn Met Trp Gln Glu Val Gly Lys Ala Met Tyr Ala
165 1                5                10                15
168 <210> SEQ ID NO: 11
169 <211> LENGTH: 13
170 <212> TYPE: PRT
171 <213> ORGANISM: Artificial
173 <220> FEATURE:
174 <223> OTHER INFORMATION: PADRE peptide
177 <220> FEATURE:
178 <221> NAME/KEY: MISC_FEATURE
179 <222> LOCATION: (3)..(3)
180 <223> OTHER INFORMATION: X is cyclohexylalanine, tyrosine, or
phenylalanine.
182 <400> SEQUENCE: 11
W--> 184 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
185 1                5                10
188 <210> SEQ ID NO: 12
189 <211> LENGTH: 58
190 <212> TYPE: PRT
191 <213> ORGANISM: Artificial
193 <220> FEATURE:
194 <223> OTHER INFORMATION: A-beta fragment-tetanus toxoid fusion protein
197 <220> FEATURE:
198 <221> NAME/KEY: MISC_FEATURE
199 <222> LOCATION: (1)..(43)
200 <223> OTHER INFORMATION: Only a contiguous fragment of residues 1-43 are
present.
201      Preferred fragments are 5-10 or 7-10 residues in length.
203 <400> SEQUENCE: 12
205 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
206 1                5                10                15
209 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
210                20                25                30
213 Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Gln Tyr Ile Lys Ala
214                35                40                45
217 Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu
218      50                55
221 <210> SEQ ID NO: 13
222 <211> LENGTH: 64
223 <212> TYPE: PRT
224 <213> ORGANISM: Artificial
226 <220> FEATURE:
227 <223> OTHER INFORMATION: A-beta fragment-tetanus toxoid fusion protein
230 <220> FEATURE:

```

## RAW SEQUENCE LISTING

DATE: 04/28/2006

PATENT APPLICATION: US/10/544,093

TIME: 09:51:41

Input Set : A:\9820US.ST25.txt

Output Set: N:\CRF4\04282006\J544093.raw

231 &lt;221&gt; NAME/KEY: MISC\_FEATURE

232 &lt;222&gt; LOCATION: (1)..(43)

233 &lt;223&gt; OTHER INFORMATION: Only a contiguous fragment of residues 1-43 are present.

234 Preferred fragments are 5-10 or 7-10 residues in length.

236 &lt;400&gt; SEQUENCE: 13

238 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

239 1 5 10 15

242 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile

243 20 25 30

246 Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Phe Asn Asn Phe Thr

247 35 40 45

250 Val Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu

251 50 55 60

254 &lt;210&gt; SEQ ID NO: 14

255 &lt;211&gt; LENGTH: 58

256 &lt;212&gt; TYPE: PRT

257 &lt;213&gt; ORGANISM: Artificial

259 &lt;220&gt; FEATURE:

260 &lt;223&gt; OTHER INFORMATION: A-beta fragment-tetanus toxoid fusion protein

263 &lt;220&gt; FEATURE:

264 &lt;221&gt; NAME/KEY: MISC\_FEATURE

265 &lt;222&gt; LOCATION: (1)..(43)

266 &lt;223&gt; OTHER INFORMATION: Only a contiguous fragment of residues 1-43 are present.

267 Preferred fragments are 5-10 or 7-10 residues in length.

269 &lt;400&gt; SEQUENCE: 14

271 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

272 1 5 10 15

275 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile

276 20 25 30

279 Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Gln Tyr Ile Lys Ala

280 35 40 45

283 Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu

284 50 55

287 &lt;210&gt; SEQ ID NO: 15

288 &lt;211&gt; LENGTH: 79

289 &lt;212&gt; TYPE: PRT

290 &lt;213&gt; ORGANISM: Artificial

292 &lt;220&gt; FEATURE:

293 &lt;223&gt; OTHER INFORMATION: A-beta fragment tetanus-toxoid fusion protein

296 &lt;220&gt; FEATURE:

297 &lt;221&gt; NAME/KEY: MISC\_FEATURE

298 &lt;222&gt; LOCATION: (1)..(43)

299 &lt;223&gt; OTHER INFORMATION: Only a contiguous fragment of residues 1-43 are present.

300 Preferred fragments are 5-10 or 7-10 residues in length.

302 &lt;400&gt; SEQUENCE: 15

304 Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys

305 1 5 10 15

308 Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile

309 20 25 30

## RAW SEQUENCE LISTING

DATE: 04/28/2006

PATENT APPLICATION: US/10/544,093

TIME: 09:51:41

Input Set : A:\9820US.ST25.txt

Output Set: N:\CRF4\04282006\J544093.raw

312 Gly Leu Met Val Gly Gly Val Val Ile Ala Thr Gln Tyr Ile Lys Ala  
 313           35                           40                           45  
 316 Asn Ser Lys Phe Ile Gly Ile Thr Glu Leu Phe Asn Asn Phe Thr Val  
 317           50                           55                           60  
 320 Ser Phe Trp Leu Arg Val Pro Lys Val Ser Ala Ser His Leu Glu  
 321 65                                   70                           75

324 &lt;210&gt; SEQ ID NO: 16

325 &lt;211&gt; LENGTH: 56

326 &lt;212&gt; TYPE: PRT

327 &lt;213&gt; ORGANISM: Artificial

329 &lt;220&gt; FEATURE:

330 &lt;223&gt; OTHER INFORMATION: Padre-A-beta fragment fusion protein

333 &lt;220&gt; FEATURE:

334 &lt;221&gt; NAME/KEY: MISC\_FEATURE

335 &lt;222&gt; LOCATION: (3)..(3)

336 &lt;223&gt; OTHER INFORMATION: X is cyclohexylalanine, tyrosine, or phenylalanine.

338 &lt;220&gt; FEATURE:

339 &lt;221&gt; NAME/KEY: MISC\_FEATURE

340 &lt;222&gt; LOCATION: (14)..(56)

341 &lt;223&gt; OTHER INFORMATION: Only a contiguous fragment of residues 14-56 are present.

342       Preferred fragments are 5-10 or 7-10 residues in length.

344 &lt;400&gt; SEQUENCE: 16

W--&gt; 346 Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asp Ala Glu

347 1                           5                           10                           15

350 Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys Leu Val Phe

351           20                           25                           30

354 Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile Gly Leu Met

355           35                           40                           45

358 Val Gly Gly Val Val Ile Ala Thr

359           50                           55

362 &lt;210&gt; SEQ ID NO: 17

363 &lt;211&gt; LENGTH: 142

364 &lt;212&gt; TYPE: PRT

365 &lt;213&gt; ORGANISM: Artificial

367 &lt;220&gt; FEATURE:

368 &lt;223&gt; OTHER INFORMATION: A-beta-A-beta-A-beta-Padre fusion protein

371 &lt;220&gt; FEATURE:

372 &lt;221&gt; NAME/KEY: MISC\_FEATURE

373 &lt;222&gt; LOCATION: (1)..(43)

374 &lt;223&gt; OTHER INFORMATION: Only a contiguous fragment of residues 1-43 are present.

375       Preferred fragments are 5-10 or 7-10 residues in length.

377 &lt;220&gt; FEATURE:

378 &lt;221&gt; NAME/KEY: MISC\_FEATURE

379 &lt;222&gt; LOCATION: (44)..(86)

380 &lt;223&gt; OTHER INFORMATION: Only a contiguous fragment of residues 44-86 are present.

381       Preferred fragments are 5-10 or 7-10 residues in length.

383 &lt;220&gt; FEATURE:

384 &lt;221&gt; NAME/KEY: MISC\_FEATURE

385 &lt;222&gt; LOCATION: (87)..(129)

RAW SEQUENCE LISTING ERROR SUMMARY  
PATENT APPLICATION: US/10/544,093

DATE: 04/28/2006  
TIME: 09:51:42

Input Set : A:\9820US.ST25.txt  
Output Set: N:\CRF4\04282006\J544093.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220>

to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:11; Xaa Pos. 3  
Seq#:16; Xaa Pos. 3  
Seq#:17; Xaa Pos. 132  
Seq#:18; Xaa Pos. 3  
Seq#:19; Xaa Pos. 46

Invalid <213> Response:

Use of "Artificial" only as "<213> Organism" response is incomplete, per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#:2,3,6,7,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27



**VERIFICATION SUMMARY**

PATENT APPLICATION: US/10/544,093

DATE: 04/28/2006

TIME: 09:51:42

Input Set : A:\9820US.ST25.txt

Output Set: N:\CRF4\04282006\J544093.raw

L:14 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:184 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:0

L:346 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16 after pos.:0

L:428 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17 after pos.:128

L:472 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18 after pos.:0

L:550 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19 after pos.:32